Trial Profile
A retrospective study of cabozantinib in the patients with metastatic clear cell renal cell carcinoma (mccRCC) in real world settings
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2018
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 15 Mar 2018 New trial record
- 10 Feb 2018 Results assessing safety and efficacy of cabozantinib in real world setting, presented at the 2018 Genitourinary Cancers Symposium.